Dasatinib (BMS-354825) is an ATP-competitive, dual SRC/ABL inhibitor. Dasatinib is a potent inhibitor of imatinib-resistant KIT activation loop mutants and induces apoptosis in mast cell and leukemic cell lines expressing these mutations. Dasatinib sensitively inhibits all members of the Src family, including c-Src, Lck, Fyn, and Yes (IC50 < 1.1nmol/L). At higher concentrations (3 to 28 nmol/L), dasatinib also inhibits the Src kinases Abl, c-Kit, PDGFR, and EphA2.

June 21, 2017

prudect name : Dasatinib (BMS-354825) is an ATP-competitive, dual SRC/ABL inhibitor. Dasatinib is a potent inhibitor of imatinib-resistant KIT activation loop mutants and induces apoptosis in mast cell and leukemic cell lines expressing these mutations. Dasatinib sensitively inhibits all members of the Src family, including c-Src, Lck, Fyn, and Yes (IC50 < 1.1nmol/L). At higher concentrations (3 to 28 nmol/L), dasatinib also inhibits the Src kinases Abl, c-Kit, PDGFR, and EphA2.
Dasatinib (BMS-354825)

Synonyms: Dasatinib (BMS-354825)CAS NO: 302962-49-8Molecular Formula: C₂₂H₂₆ClN₇O₂SMolecular Weight: 488.01Purity: 99%Solubility: In DMSOStorage: -20°C

ACT-128800 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18511055